Update

Research Focus

235 TACE-dependent EGF receptor activation in angiotensin-II-induced kidney disease
Bukhilar H. Shah and Kevin J. Catt

Letter

237 Homeopathy: the case in favour
John Saxton

Opinion

240 Computational neuropharmacology: dynamical approaches in drug discovery
Ildiko Aradi and Péter Erdi

244 Corticosteroid effects in the brain: U-shape it
Marian Joëls

Review

251 Clinical proteomics: searching for better tumour markers with SELDI-TOF mass spectrometry
Judith Y.M.N. Engwegen, Marie-Christine W. Gast, Jan H.M. Schellens and Jos H. Beijnen

260 Genetic diseases associated with heterotrimeric G proteins
Lee S. Weinstein, Min Chen, Tao Xie and Jie Liu

267 Targets in ALS: designing multidrug therapies
Maria Teresa Carri, Giuliano Grignaschi and Caterina Bendotti

274 Principles: When there should be no difference – how to fail to reject the null hypothesis
Michael J. Lew

279 The hypothalamic H1 receptor: a novel therapeutic target for disrupting diurnal feeding rhythm and obesity
Takayuki Masaki and Hironobu Yoshimatsu

Forthcoming articles

The ClC-3 Cl channel in cell volume regulation, proliferation and apoptosis in vascular smooth muscle cells
Yong-Yuan Guan, Guan-Lei Wang and Jia-Guo Zhou

Emerging cancer therapeutic opportunities target DNA-repair systems
Jian Ding, Ze-Hong Miao, Ling-Hua Meng and Mei-Yu Geng

Using positron emission tomography to facilitate CNS drug development
Chi-Ming Lee and Lars Farde

Biomechanopharmacology: a new borderline discipline
Fulong Liao, Min Li, Dong Han, Jun Cao and Keji Chen

PKD at the crossroads of DAG and PKC signaling
Giming J. Wang

IUPHAR: from San Francisco to Beijing
Paul M. Vanhoutte

Cover: Computational approaches that adopt dynamical models are widely accepted in basic and clinical neuroscience research as indispensable tools with which to understand normal and pathological neuronal mechanisms. On pp. 240–243, Ildiko Aradi and Péter Erdi discuss a promising and innovative discipline ('computational neuropharmacology') that could open new avenues in drug discovery for the development of new therapies for neurological and psychiatric disorders. Design by Kate Jones.